What is claimed is:

1. A method for reducing lipoprotein(a) (Lp(a)) levels, the method comprising selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor.

2. The method of claim 1, wherein the patient is selected on the basis of a serum Lp(a) level greater than about 20 mg/dL.

3. The method of claim 2, wherein the patient is selected on the basis of a serum Lp(a) level greater than about 100 mg/dL.

4. The method of any one of claims 1 to 3, wherein prior to or at the time of administration of the pharmaceutical composition, the patient is diagnosed with or identified as being at risk of developing a cardiovascular disease or disorder.

5. The method of claim 4, wherein the cardiovascular disease or disorder is selected from the group consisting of coronary artery disease, acute myocardial infarction, asymptomatic carotid atherosclerosis, stroke, and peripheral artery occlusive disease.

6. The method of claim 4, wherein the cardiovascular disease or disorder is hypercholesterolemia.

7. The method of claim 6, wherein the hypercholesterolemia is heterozygous Familial Hypercholesterolemia (heFH).

8. The method of claim 6, wherein the hypercholesterolemia is not Familial Hypercholesterolemia (nonFH).

9. The method of any one of claims 1 to 3, wherein prior to or at the time of administration of the pharmaceutical composition, the patient is diagnosed with or identified as being at risk of developing a thrombotic occlusive disease or disorder.

10. The method of claim 9, wherein the thrombotic occlusive disease or disorder is selected from the group consisting of pulmonary embolism and central retinal vein occlusion.

11. The method of any one of claims 1 to 10, wherein the PCSK9 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds PCSK9.

12. The method of claim 11, wherein the pharmaceutical composition comprises 20 mg to 200 mg of the PCSK9 inhibitor.

13. The method of claim 12, wherein the pharmaceutical composition comprises 50 mg to 150 mg of the PCSK9 inhibitor.

14. The method of claim 13, wherein the pharmaceutical composition comprises 50 mg of the PCSK9 inhibitor.

15. The method of claim 13, wherein the pharmaceutical composition comprises 100 mg of the PCSK9 inhibitor.

16. The method of claim 13, wherein the pharmaceutical composition comprises 150 mg of the PCSK9 inhibitor.

17. The method of any one of claims 11 to 16, wherein the antibody or antigen binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 90/92 and 218/226.

18. The method of claim 17, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232.

19. The method of claim 18, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:218 and an LCVR having the amino acid sequence of SEQ ID NO:226.

20. The method of claim 17, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:76, 78, 80, 84, 86 and 88.

21. The method of claim 20, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:90 and an LCVR having the amino acid sequence of SEQ ID NO:92.

22. The method of any one of claims 11 to 16, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

23. The method of any one of claims 11 to 16, wherein the antibody or antigen-binding fragment thereof competes for binding to PCSK9 with an antibody comprising heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

24. The method of any one of claims 1 to 23, wherein the patient is on a therapeutic statin regimen at the time of or just prior to administration of the pharmaceutical composition.

25. The method of claim 24, wherein the therapeutic statin regimen comprises a statin selected from the group consisting of cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin and pravastatin.

26. The method of claim 25, wherein the statin is atorvastatin.

27. The method of any one of claims 1 to 23, wherein the patient is not on a therapeutic statin regimen at the time of administration of the pharmaceutical composition.

28. A pharmaceutical composition comprising a PCSK9 inhibitor for use in reducing lipoprotein(a) (Lp(a)) levels in a patient who exhibits an elevated serum Lp(a) level.

29. The pharmaceutical composition of claim 28, wherein the patient exhibits a serum Lp(a) level greater than about 20 mg/dL.

30. The pharmaceutical composition of claim 29, wherein the patient exhibits a serum Lp(a) level greater than about 100 mg/dL.

31. The pharmaceutical composition of any one of claims 28 to 30, wherein the patient is diagnosed with or identified as being at risk of developing a cardiovascular disease or disorder.

32. The pharmaceutical composition of claim 31, wherein the cardiovascular disease or disorder is selected from the group consisting of coronary artery disease, acute myocardial infarction, asymptomatic carotid atherosclerosis, stroke, and peripheral artery occlusive disease.

33. The pharmaceutical composition of claim 31, wherein the cardiovascular disease or disorder is hypercholesterolemia.

34. The pharmaceutical composition of claim 33, wherein the hypercholesterolemia is heterozygous Familial Hypercholesterolemia (heFH).

35. The pharmaceutical composition of claim 33, wherein the hypercholesterolemia is not Familial Hypercholesterolemia (nonFH).

36. The pharmaceutical composition of any one of claims 28 to 30, wherein the patient is diagnosed with or identified as being at risk of developing a thrombotic occlusive disease or disorder.

37. The pharmaceutical composition of claim 36, wherein the thrombotic occlusive disease or disorder is selected from the group consisting of pulmonary embolism and central retinal vein occlusion.

38. The pharmaceutical composition of any one of claims 28 to 37, wherein the PCSK9 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds PCSK9.

39. The pharmaceutical composition of claim 38, wherein the pharmaceutical composition comprises 20 mg to 200 mg of the PCSK9 inhibitor.

40. The pharmaceutical composition of claim 39, wherein the pharmaceutical composition comprises 50 mg to 150 mg of the PCSK9 inhibitor.

41. The pharmaceutical composition of claim 40, wherein the pharmaceutical composition comprises 50 mg of the PCSK9 inhibitor.

42. The pharmaceutical composition of claim 40, wherein the pharmaceutical composition comprises 100 mg of the PCSK9 inhibitor.

43. The pharmaceutical composition of claim 40, wherein the pharmaceutical composition comprises 150 mg of the PCSK9 inhibitor.

44. The pharmaceutical composition of any one of claims 38 to 43, wherein the antibody or antigen binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 90/92 and 218/226.

45. The pharmaceutical composition of claim 44, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232.

46. The pharmaceutical composition of claim 45, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:218 and an LCVR having the amino acid sequence of SEQ ID NO:226.

47. The pharmaceutical composition of claim 44, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:76, 78, 80, 84, 86 and 88.

48. The pharmaceutical composition of claim 47, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:90 and an LCVR having the amino acid sequence of SEQ ID NO:92.

49. The pharmaceutical composition of any one of claims 38 to 43, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

50. The pharmaceutical composition of any one of claims 38 to 43, wherein the antibody or antigen-binding fragment thereof competes for binding to PCSK9 with an antibody comprising heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

51. The pharmaceutical composition of any one of claims 28 to 50, wherein the patient is on a therapeutic statin regimen.

52. The pharmaceutical composition of claim 51, wherein the therapeutic statin regimen comprises a statin selected from the group consisting of cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin and pravastatin.

53. The pharmaceutical composition of claim 52, wherein the statin is atorvastatin.

54. The pharmaceutical composition of any one of claims 28 to 50, wherein the patient is not on a therapeutic statin regimen.

What is claimed is:

1. A pharmaceutical composition comprising a PCSK9 inhibitor for use in reducing lipoprotein(a) (Lp(a)) levels in a patient who exhibits an elevated serum Lp(a) level.

2. The pharmaceutical composition of claim 1, wherein the patient exhibits a serum Lp(a) level greater than about 20 mg/dL.

3. The pharmaceutical composition of claim 2, wherein the patient exhibits a serum Lp(a) level greater than about 100 mg/dL.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein the patient is diagnosed with or identified as being at risk of developing a cardiovascular disease or disorder.

5. The pharmaceutical composition of claim 4, wherein the cardiovascular disease or disorder is selected from the group consisting of coronary artery disease, acute myocardial infarction, asymptomatic carotid atherosclerosis, stroke, and peripheral artery occlusive disease.

6. The pharmaceutical composition of claim 4, wherein the cardiovascular disease or disorder is hypercholesterolemia.

7. The pharmaceutical composition of claim 6, wherein the hypercholesterolemia is heterozygous Familial Hypercholesterolemia (heFH).

8. The pharmaceutical composition of claim 6, wherein the hypercholesterolemia is not Familial Hypercholesterolemia (nonFH).

9. The pharmaceutical composition of any one of claims 1 to 3, wherein the patient is diagnosed with or identified as being at risk of developing a thrombotic occlusive disease or disorder.

10. The pharmaceutical composition of claim 9, wherein the thrombotic occlusive disease or disorder is selected from the group consisting of pulmonary embolism and central retinal vein occlusion.

11. The pharmaceutical composition of any one of claims 1 to 10, wherein the PCSK9 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds PCSK9.

12. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition comprises 20 mg to 200 mg of the PCSK9 inhibitor.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition comprises 50 mg to 150 mg of the PCSK9 inhibitor.

14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition comprises 50 mg of the PCSK9 inhibitor.

15. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition comprises 100 mg of the PCSK9 inhibitor.

16. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition comprises 150 mg of the PCSK9 inhibitor.

17. The pharmaceutical composition of any one of claims 11 to 16, wherein the antibody or antigen binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 90/92 and 218/226.

18. The pharmaceutical composition of claim 17, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232.

19. The pharmaceutical composition of claim 18, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:218 and an LCVR having the amino acid sequence of SEQ ID NO:226.

20. The pharmaceutical composition of claim 17, wherein the antibody or antigen-binding fragment thereof comprises heavy and light chain CDR amino acid sequences having SEQ ID NOs:76, 78, 80, 84, 86 and 88.

21. The pharmaceutical composition of claim 20, wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:90 and an LCVR having the amino acid sequence of SEQ ID NO:92.

22. The pharmaceutical composition of any one of claims 11 to 16, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on PCSK9 as an antibody comprising heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

23. The pharmaceutical composition of any one of claims 11 to 16, wherein the antibody or antigen-binding fragment thereof competes for binding to PCSK9 with an antibody comprising heavy and light chain CDR amino acid sequences having SEQ ID NOs:220, 222, 224, 228, 230 and 232; or SEQ ID NOs: 76, 78, 80, 84, 86 and 88.

24. The pharmaceutical composition of any one of claims 1 to 23, wherein the patient is on a therapeutic statin regimen.

25. The pharmaceutical composition of claim 24, wherein the therapeutic statin regimen comprises a statin selected from the group consisting of cerivastatin, atorvastatin, simvastatin, pitavastatin, rosuvastatin, fluvastatin, lovastatin and pravastatin.

26. The pharmaceutical composition of claim 25, wherein the statin is atorvastatin.

27. The pharmaceutical composition of any one of claims 1 to 23, wherein the patient is not on a therapeutic statin regimen.